Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |1 February 2005

Cyclooxygenase-2 Inhibitors and Heart Attacks: Varying Effects? Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled “Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction.” It is in the 1 February 2005 issue of Annals of Internal Medicine (volume 142, pages 157-164). The authors are S.E. Kimmel, J.A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B.L. Strom.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

What is the problem and what is known about it so far?

People commonly use nonsteroidal anti-inflammatory drugs (NSAIDs) to relieve pain. Examples of older NSAIDs include aspirin, ibuprofen (Advil or Motrin), and naproxen (Aleve). Although these older NSAIDs are fairly safe, they can irritate the lining of the stomach and can cause ulcers and bleeding. Cyclooxygenase-2 (COX-2) inhibitors are a new type of selective NSAIDs. Examples of COX-2 inhibitors are celecoxib (Celebrex), rofecoxib (Vioxx), and valdecoxib (Bextra). They inhibitors do not injure the stomach lining as much as older NSAIDs do and cause fewer stomach problems and ulcers. However, they also cost more and require a doctor's prescription. Also, some COX-2 inhibitors increase the risk for heart disease. For example, rofecoxib was withdrawn from the market in September 2004 because a large trial found that it increased the risk for heart attacks and strokes. We do not know whether other COX-2 inhibitors have similar or different risks.

Why did the researchers do this particular study?

To see whether the risk for having a heart attack was similar among people taking rofecoxib; celecoxib; and older, nonselective NSAIDs.

Who was studied?

1718 patients with a first, nonfatal heart attack and 6800 adults with no history of a heart attack. All patients were 40 to 75 years of age from 5 counties in Pennsylvania.

How was the study done?

The researchers identified patients with recent heart attacks who were discharged from 36 hospitals between May 1998 and December 2002. They also identified adults with no history of a heart attack who were living in the same geographic region. They interviewed all participants by telephone and asked them several questions about past NSAID use. Patients with heart attacks reported use during the week before to their heart attack, while others reported use during the week before the interview. The researchers then compared NSAID use between patients with heart attacks and those with no history of a heart attack.

What did the researchers find?

Older NSAIDs were associated with a decreased risk for heart attack. Almost one third of the adults with no history of a heart attack reported taking older NSAIDs, while only about one fifth of those with a heart attack reported using these drugs. About 2.5% of the adults in both groups reported that they took 1 of 2 COX-2 inhibitors that were examined in the study. Use of rofecoxib was associated with a 2.72-higher odds of heart attack than was use of celecoxib. Rofecoxib was also associated with a higher odds of heart attack compared with older NSAIDs. Whether celecoxib was associated with a similar odds of heart attack compared with older NSAIDs was not clear.

What were the limitations of the study?

Only about 50% of eligible adults completed interviews. The study was not a randomized trial. Drug use was self-reported.

What are the implications of the study?

The risk for heart disease with rofecoxib and celecoxib may differ.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Cyclooxygenase-2 Inhibitors and Heart Attacks: Varying Effects?. Ann Intern Med. 2005;142:I–21. doi: 10.7326/0003-4819-142-3-200502010-00001

Download citation file:

  • RIS (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2018

×
Permissions

Published: Ann Intern Med. 2005;142(3):I-21.

DOI: 10.7326/0003-4819-142-3-200502010-00001

©
2005 American College of Physicians
0 Citations

See Also

Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
View MoreView Less

Related Articles

The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults
Annals of Internal Medicine; 142 (7): 481-489
Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
Annals of Internal Medicine; 142 (3): 157-164
Low-Dose Aspirin to Reduce the Risk for Myocardial Infarction Among Patients With Coronary Stents Undergoing Noncardiac Surgery
Annals of Internal Medicine; 168 (4): 289-290
Annals for Educators - 16 May 2017
Annals of Internal Medicine; 166 (10): ED10
View MoreView Less

Journal Club

Review: β-blockers do not reduce mortality in myocardial infarction in the reperfusion era
Annals of Internal Medicine; 162 (6): JC3
Review: In high-risk patients, fatty acid supplementation does not prevent coronary events
Annals of Internal Medicine; 161 (6): JC7
In noncardiac surgery, perioperative aspirin did not reduce death or MI at 30 d but increased major bleeding
Annals of Internal Medicine; 161 (4): JC5
Red blood cell transfusion after PCI was associated with increased mortality, MI, and stroke
Annals of Internal Medicine; 160 (12): JC12
View MoreView Less

Related Topics

Acute Coronary Syndromes
Cardiology
Coronary Heart Disease
Emergency Medicine

Acute Coronary Syndromes, Cardiology, Coronary Heart Disease, Emergency Medicine.

PubMed Articles

Fosphenytoin for control of electrical storm in acute myocardial infarction and Purkinje fiber mediated arrhythmias.
Pacing Clin Electrophysiol 2018.
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Pharmacoepidemiol Drug Saf 2018.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Online First RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards

  • Personae Photography Prize
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×